An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The development of blood-based biomarkers of Alzheimer’s disease (AD) pathology as tools for screening the general population, and as the first step in a multistep process to determine which non-demented individuals are at greatest risk of developing AD dementia, is essential. Proteins that are reflective of AD pathology, such as amyloid beta 42 (Aβ42), tau proteins [total tau (T-tau) and phosphorylated tau (P-tau)], and neurofilament light chain (NfL), are detectable in the blood. However, a major challenge in measuring these blood-based proteins is that their concentrations are much lower in plasma or serum than in the cerebrospinal fluid. Single molecule array (SiMoA) is an ultrasensitive technology that can detect proteins in blood at sub-femtomolar concentrations (i.e., 10−16 M). In this review, we focus on the utility of SiMoA assays for the measurement of plasma or serum Aβ42, P-tau, T-tau, and NfL levels and discuss future directions.

Original languageEnglish (US)
Pages (from-to)73-82
Number of pages10
JournalNeurology and Therapy
Volume8
DOIs
StatePublished - Dec 1 2019

Fingerprint

Alzheimer Disease
Intermediate Filaments
Amyloid
Blood Proteins
Pathology
Light
tau Proteins
Serum
Cerebrospinal Fluid
Biomarkers
Technology
Population
Proteins

Keywords

  • Alzheimer’s disease
  • Amyloid-beta
  • Blood biomarkers
  • Neurofilament
  • Single molecule array technology
  • Tau

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform. / Li, Danni; Mielke, Michelle M.

In: Neurology and Therapy, Vol. 8, 01.12.2019, p. 73-82.

Research output: Contribution to journalReview article

@article{495d47c7165e4abd944e2a6c60da31b7,
title = "An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform",
abstract = "The development of blood-based biomarkers of Alzheimer’s disease (AD) pathology as tools for screening the general population, and as the first step in a multistep process to determine which non-demented individuals are at greatest risk of developing AD dementia, is essential. Proteins that are reflective of AD pathology, such as amyloid beta 42 (Aβ42), tau proteins [total tau (T-tau) and phosphorylated tau (P-tau)], and neurofilament light chain (NfL), are detectable in the blood. However, a major challenge in measuring these blood-based proteins is that their concentrations are much lower in plasma or serum than in the cerebrospinal fluid. Single molecule array (SiMoA) is an ultrasensitive technology that can detect proteins in blood at sub-femtomolar concentrations (i.e., 10−16 M). In this review, we focus on the utility of SiMoA assays for the measurement of plasma or serum Aβ42, P-tau, T-tau, and NfL levels and discuss future directions.",
keywords = "Alzheimer’s disease, Amyloid-beta, Blood biomarkers, Neurofilament, Single molecule array technology, Tau",
author = "Danni Li and Mielke, {Michelle M.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1007/s40120-019-00164-5",
language = "English (US)",
volume = "8",
pages = "73--82",
journal = "Neurology and Therapy",
issn = "2193-8253",
publisher = "Springer Healthcare",

}

TY - JOUR

T1 - An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform

AU - Li, Danni

AU - Mielke, Michelle M.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The development of blood-based biomarkers of Alzheimer’s disease (AD) pathology as tools for screening the general population, and as the first step in a multistep process to determine which non-demented individuals are at greatest risk of developing AD dementia, is essential. Proteins that are reflective of AD pathology, such as amyloid beta 42 (Aβ42), tau proteins [total tau (T-tau) and phosphorylated tau (P-tau)], and neurofilament light chain (NfL), are detectable in the blood. However, a major challenge in measuring these blood-based proteins is that their concentrations are much lower in plasma or serum than in the cerebrospinal fluid. Single molecule array (SiMoA) is an ultrasensitive technology that can detect proteins in blood at sub-femtomolar concentrations (i.e., 10−16 M). In this review, we focus on the utility of SiMoA assays for the measurement of plasma or serum Aβ42, P-tau, T-tau, and NfL levels and discuss future directions.

AB - The development of blood-based biomarkers of Alzheimer’s disease (AD) pathology as tools for screening the general population, and as the first step in a multistep process to determine which non-demented individuals are at greatest risk of developing AD dementia, is essential. Proteins that are reflective of AD pathology, such as amyloid beta 42 (Aβ42), tau proteins [total tau (T-tau) and phosphorylated tau (P-tau)], and neurofilament light chain (NfL), are detectable in the blood. However, a major challenge in measuring these blood-based proteins is that their concentrations are much lower in plasma or serum than in the cerebrospinal fluid. Single molecule array (SiMoA) is an ultrasensitive technology that can detect proteins in blood at sub-femtomolar concentrations (i.e., 10−16 M). In this review, we focus on the utility of SiMoA assays for the measurement of plasma or serum Aβ42, P-tau, T-tau, and NfL levels and discuss future directions.

KW - Alzheimer’s disease

KW - Amyloid-beta

KW - Blood biomarkers

KW - Neurofilament

KW - Single molecule array technology

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=85076354986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076354986&partnerID=8YFLogxK

U2 - 10.1007/s40120-019-00164-5

DO - 10.1007/s40120-019-00164-5

M3 - Review article

AN - SCOPUS:85076354986

VL - 8

SP - 73

EP - 82

JO - Neurology and Therapy

JF - Neurology and Therapy

SN - 2193-8253

ER -